血管内皮生长因子抑制剂治疗视网膜新生血管性疾病  

Application of vascular endothelial growth factor inhibitor for retinal neovascualrization disease

作　　者：常以力[1] 章福保[1] 曾莉[2] 

机构地区：[1]南昌大学研究生院医学部09级,江西省南昌市330000 [2]南昌大学第一附属医院门诊部眼科,江西省南昌市330000

出　　处：《眼科新进展》2011年第6期594-597,共4页Recent Advances in Ophthalmology

摘　　要：视网膜新生血管性疾病是致盲的主要病因,早期预防、控制视网膜新生血管的发生发展显得尤为重要。目前,关于视网膜新生血管性疾病的确切发病机制尚不清楚,但对血管内皮生长因子(vascular endothelial growth factor,VEGF)在其形成过程中起关键作用已达成共识,现在已有多种VEGF抑制剂被用于治疗眼部新生血管性疾病。现将治疗视网膜新生血管性疾病的最新几种VEGF抑制剂作一综述。Retinal neovascularization disease is the main cause of blinding.Early prevention and control are important for the development of retinal neovascularization diseases.Presently,the exact pathogenesis of retinal neovascularization diseases is still quite unknown.However,the importance of vascular endothelial growth factor（VEGF）has already come to a common view.Thus,many types of VEGF inhibitior have been used to treat ocular neovascularization diseases.In this article,a couple of the latest VEGF inhibitor for retinal neovascularization diseases is reviewed.

关 键 词：血管内皮生长因子 视网膜新生血管性病变 AVASTIN MACUGEN LUCENTIS 

分 类 号：R777.2[医药卫生—眼科]